HUTCHMED's Sovleplenib Meets Phase III Goal In WAIHA, Showing 66% Durable Response Rate; Stock Up

HUTCHMED (China) Limited (HCM), a commercial-stage biopharmaceutical company, announced on Friday results from the Phase III portion of the ESLIM-02 study of Sovleplenib in patients with warm antibody autoimmune hemolytic anaemia (wAIHA).